Tango Therapeutics, Inc. Increase (Decrease) in Deferred Revenue
Tango Therapeutics, Inc. (TNGX) reported Increase (Decrease) in Deferred Revenue of -$62.38 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2026-08-11
- Tango Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2025-12-31 was $0.00.
- Tango Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2025-09-30 was -$53.81M.
- Tango Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2025-06-30 was -$3.18M.
- Tango Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2025-03-31 was -$5.39M.
- Tango Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2025 was -$62.38M.
- Tango Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2024 was -$29.97M.
- Tango Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2023 was -$31.53M.
- Tango Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2022 was -$16.86M.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$53.81M derived: sum of 2 quarters · filed 2026-03-05 | -$56.99M derived: sum of 3 quarters · filed 2026-08-11 | -$62.38M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$53.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$56.99M derived: sum of 2 quarters · filed 2026-08-11 | -$62.38M 10-Q · filed 2025-11-04 | -$66.50M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$3.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$8.57M 10-Q · filed 2026-08-11 | -$12.69M derived: sum of 3 quarters · filed 2026-08-11 | -$24.30M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$5.39M 10-Q · filed 2026-05-13 | -$9.51M derived: sum of 2 quarters · filed 2026-05-13 | -$21.11M derived: sum of 3 quarters · filed 2026-05-13 | -$28.89M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$4.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$15.72M derived: sum of 2 quarters · filed 2026-03-05 | -$23.50M derived: sum of 3 quarters · filed 2026-03-05 | -$29.97M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$11.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$19.38M derived: sum of 2 quarters · filed 2025-11-04 | -$25.85M 10-Q · filed 2025-11-04 | -$31.28M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-06-30 | -$7.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$14.25M 10-Q · filed 2025-08-05 | -$19.68M derived: sum of 3 quarters · filed 2026-03-05 | -$30.41M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-03-31 | -$6.47M 10-Q · filed 2025-05-12 | -$11.90M derived: sum of 2 quarters · filed 2026-03-05 | -$22.63M derived: sum of 3 quarters · filed 2026-03-05 | -$32.23M derived: sum of 4 quarters · filed 2026-03-05 |
| 2023-12-31 | -$5.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$16.16M derived: sum of 2 quarters · filed 2026-03-05 | -$25.76M derived: sum of 3 quarters · filed 2026-03-05 | -$31.53M 10-K · filed 2026-03-05 |
| 2023-09-30 | -$10.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$20.33M derived: sum of 2 quarters · filed 2024-11-06 | -$26.10M 10-Q · filed 2024-11-06 | -$30.51M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$9.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$15.36M 10-Q · filed 2024-08-07 | -$19.77M derived: sum of 3 quarters · filed 2025-02-27 | -$24.70M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$5.77M 10-Q · filed 2024-05-08 | -$10.18M derived: sum of 2 quarters · filed 2025-02-27 | -$15.10M derived: sum of 3 quarters · filed 2025-02-27 | -$18.87M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$4.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$9.33M derived: sum of 2 quarters · filed 2025-02-27 | -$13.10M derived: sum of 3 quarters · filed 2025-02-27 | -$16.86M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$4.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$8.69M derived: sum of 2 quarters · filed 2023-11-08 | -$12.45M 10-Q · filed 2023-11-08 | -$16.16M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | -$3.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$7.53M 10-Q · filed 2023-08-07 | -$11.24M derived: sum of 3 quarters · filed 2023-08-07 | -$10.03M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | -$3.76M 10-Q · filed 2023-05-09 | -$7.47M derived: sum of 2 quarters · filed 2023-05-09 | -$6.26M derived: sum of 3 quarters · filed 2023-05-09 | -$11.41M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$3.72M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | -$2.50M derived: sum of 2 quarters · filed 2023-03-27 | -$7.66M derived: sum of 3 quarters · filed 2023-03-27 | -$12.04M 10-K · filed 2023-03-27 |
| 2021-09-30 | $1.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$3.94M derived: sum of 2 quarters · filed 2022-11-10 | -$8.33M 10-Q · filed 2022-11-10 | -$15.47M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$5.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | -$9.54M 10-Q · filed 2022-08-10 | -$16.68M derived: sum of 3 quarters · filed 2022-08-10 | |
| 2021-03-31 | -$4.39M 10-Q · filed 2022-05-11 | -$11.53M derived: sum of 2 quarters · filed 2022-05-11 | ||
| 2020-12-31 | -$7.14M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $119.08M 10-K · filed 2022-03-28 | ||
| 2020-09-30 | $126.22M 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |